The Smarter Diagnostic Solution for Bloodstream Infections
The LIAISON PLEX® bloodstream infection portfolio (BSI) features three FDA-cleared multiplex molecular assays, offering comprehensive pathogen detection for 48 bacterial and fungal species associated with bloodstream infections and sepsis, and 12 clinically significant antimicrobial resistance genes, enabling physicians to optimize antimicrobial treatment in a timely manner, improve patient management, and potentially reduce hospital costs.
Our LIAISON PLEX® BSI portfolio is intuitively designed to ensure seamless integration into your standard-of-care workflow. Guided by Gram stain results, they empower healthcare professionals to make informed decisions, streamline testing, and tailor diagnostics to meet patient-specific needs.
